
Sign up to save your podcasts
Or


In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out!
To learn more about the topics in this episode:
This week's episode is brought to you by Cencora.
See omnystudio.com/listener for privacy information.
By Fierce Life Sciences4.1
1212 ratings
In this week’s episode of "The Top Line," Fierce Biotech’s Gabrielle Masson and Darren Incorvaia sit down to discuss a recent special report from Fierce Biotech, ranking the top 10 R&D budgets from 2024.
Did Merck hold on to its 2023 crown? And did any new faces crack this year’s list? Listen to find out!
To learn more about the topics in this episode:
This week's episode is brought to you by Cencora.
See omnystudio.com/listener for privacy information.

3,228 Listeners

1,713 Listeners

4,420 Listeners

2,175 Listeners

386 Listeners

1,993 Listeners

355 Listeners

1,649 Listeners

154 Listeners

96 Listeners

3,992 Listeners

1,448 Listeners

337 Listeners

34 Listeners

170 Listeners